Nascent Biotech's Reverse Merger Round

Nascent Biotech raised a round of funding on July 29, 2014. Investors include Nascent Biotech.

Nascent Biotech (NBI) is a biotechnology company developing human Monoclonal Antibodies (mAb's) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ev…

Articles about Nascent Biotech's Reverse Merger Round: